A Conserved cis-Acting Element in the Parathyroid Hormone 3'-Untranslated Region Is Sufficient for Regulation of RNA Stability by Calcium and Phosphate*

Rachel Kilav, Justin Silver, and Tally Naveh-ManyDagger

From the Minerva Center for Calcium and Bone Metabolism, Nephrology Services, Hadassah University Hospital, Jerusalem il-91120, Israel

Received for publication, June 22, 2000, and in revised form, November 16, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Calcium and phosphate regulate parathyroid hormone (PTH) gene expression post-transcriptionally by changes in protein-PTH mRNA 3'-untranslated region (UTR) interactions, which determine PTH mRNA stability. We have identified the protein binding sequence in the PTH mRNA 3'-UTR and determined its functionality. The protein-binding element was identified by binding, competition, and antisense oligonucleotide interference. The sequence was preserved among species suggesting its importance. To study its functionality in the context of another RNA, a 63-base pair cDNA PTH sequence was fused to the growth hormone (GH) gene. There is no parathyroid (PT) cell line and therefore an in vitro degradation assay was used to determine the stability of transcripts for PTH, GH, and a chimeric GH-PTH 63 nucleotides with PT cytosolic proteins. The full-length PTH transcript was stabilized by PT proteins from rats fed a low calcium diet and destabilized by proteins from rats fed a low phosphate diet, correlating with PTH mRNA levels in vivo. These PT proteins did not affect the native GH transcript. However, the chimeric GH transcript was stabilized by low calcium PT proteins and destabilized by low phosphate PT proteins, similar to the PTH full-length transcript. Therefore, we have identified a PTH RNA-protein binding region and shown that it is sufficient to confer responsiveness to calcium and phosphate in a reporter gene. This defined element in the PTH mRNA 3'-UTR is necessary and sufficient for the regulation of PTH mRNA stability by calcium and phosphate.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Parathyroid hormone (PTH)1 acts to maintain serum calcium within a narrow physiological range (1). A 7-transmembranous calcium-sensing receptor on the parathyroid (PT) cell recognizes small changes in serum-ionized calcium and regulates PTH secretion (2). Low serum calcium increases PTH secretion, PTH mRNA levels (3), and if prolonged, PT cell proliferation (4). PTH then acts to correct serum calcium by mobilizing calcium from bone and increasing renal reabsorption of calcium. Phosphate also regulates the PT, with low serum phosphate decreasing serum PTH, PTH mRNA levels, and PT cell proliferation (4-8).

The effects of dietary calcium and phosphate on PTH gene expression are both post-transcriptional (5, 9). The PTH cDNA consists of three exons coding for the 5'-UTR (exon I), the prepro region of PTH (exon II), and the structural hormone together with the 3'-UTR (exon III) (10, 11). The rat 3'-UTR is 239 nt long out of the 712 nt of the full-length PTH RNA (11). The 3'-UTR is 42% conserved between human and rat, while the coding region is 78% conserved at the nt level (11).

We have shown that cytosolic proteins from PTs bind to the 3'-UTR of the rat PTH mRNA (9). PT proteins from hypocalcemic rats show increased binding to the PTH mRNA 3'-UTR by mobility shift and UV cross-linking assays and this protein-RNA binding is decreased with hypophosphatemic PT proteins. Thus the level of protein-RNA binding directly correlates with PTH mRNA levels. Since there is no PT cell line, an in vitro PTH RNA stability assay was utilized. This assay showed stabilization of the PTH transcript by hypocalcemic PT proteins and marked instability with PT hypophosphatemic proteins (9). A PTH transcript that did not include the 3'-UTR was not degraded by PT proteins in this assay. These studies indicate that there are instability regions in the PTH mRNA 3'-UTR that are protected by RNA-binding proteins. We have recently identified two proteins that bind the PTH mRNA 3'-UTR (12, 13). One protein, AUF1, was identified by affinity chromatography and was shown to stabilize the PTH transcript in an in vitro degradation assay with PT proteins (12). In other RNAs such as proto-oncogenes and cytokines, that have a short half-life, AUF1 is associated with destabilization of the transcripts (14). A second protein, dynein light chain (Mr 8000) or LC8 was identified by expression cloning and was shown to mediate the binding of the PTH mRNA to microtubules (13). LC8 may have a role in the intracellular localization of PTH mRNA in the PT cell rather than in the stability of PTH mRNA.

We have now identified the minimal protein binding sequence in the PTH mRNA 3'-UTR by binding assays, competition experiments, and oligonucleotide binding interference analysis. To demonstrate the functionality of this sequence 63 base pairs of the PTH mRNA 3'-UTR which included the 26-nt protein-binding element and 5'- and 3'-flanking nt were inserted into the GH gene. Using in vitro degradation assays with cytosolic extracts from parathyroid glands we demonstrated that this element altered GH mRNA stability. The 63-nt element also reduced the stability of a random transcript of the pCRII polylinker, in contrast to a truncated element inserted into the polylinker which did not bind PT proteins. In addition, inserting the 63-nt binding sequence into GH RNA conferred responsiveness of the chimeric transcript to PT proteins from low calcium and low phosphate rats, similar to the effects of these proteins on the full-length native PTH transcript. These results demonstrate that the protein-binding region in the PTH mRNA 3'-UTR is sufficient to determine PTH mRNA stability in response to changes in serum calcium and phosphate.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Animals-- Weanling male Sabra rats were fed a normal calcium (0.6%), normal phosphate (0.3%) diet; a low calcium (0.02%), normal phosphate (0.3%) diet; or a low phosphate (0.02%), normal calcium (0.6%) diet (Teklad, IL) for 3 weeks. At 3 weeks the thyroparathyroid tissue was removed under pentobarbital anesthesia and blood samples were taken for serum calcium and phosphate. The low calcium diet resulted in a serum calcium of 4.6 ± 0.4 mg/dl (control = 11.2 ± 0.3 mg/dl). The low phosphate diet resulted in a serum phosphate of 4.0 ± 0.6 mg/dl (control = 9.8 ± 0.7 mg/dl) and serum calcium of 12.4 ± 0.8 mg/dl.

Cytoplasmic Protein Purification-- Cytoplasmic thyroparathyroid proteins (S100) for protein-RNA binding were extracted by a modification of the method of Dignam et al. (15). Tissues were removed from the rats and immediately washed in cold phosphate-buffered saline. The tissue was homogenized in 5 volumes of buffer A containing 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride, and incubated on ice for 10 min. After centrifugation at 600 × g for 10 min (4 °C) the supernatant was carefully decanted, mixed with 0.1 volumes of buffer B containing 0.3 M HEPES, 1.4 M KCl, and 0.03 M MgCl2, and centrifuged (4 °C) at 100,000 × g for 1 h (Beckman Type TL-100). For RNA degradation assays the S100 fraction was prepared as previously described (9) by homogenizing the tissue in 2 volumes of 10 mM Tris-HCl, pH 7.4, 0.5 mM DTT, 10 mM KCl, 1.5 mM MgCl2. 0.1 Volume of the extraction buffer (1.5 mM KCl, 15 mM MgCl2, 100 mM Tris-HCl, pH 7.4, 5 mM DTT, was added and the homogenate was centrifuged at 14,000 × g for 2 min to pellet the nuclei. The supernatant was centrifuged at 100,000 × g for 1 h at 4 °C. Cytoplasmic extracts were immediately frozen at -80 °C in aliquots. Protein concentration was determined by O.D. densitometry (595 µm wavelength) using a Bradford reagent (Bio-Rad).

RNA Transcripts and Probes-- Labeled and unlabeled RNA was transcribed from linearized plasmids using an RNA production kit (Promega, WI) and the appropriate RNA polymerases. The specific activity of the RNA probe was 0.5-1.0 × 106 cpm/ng. For competition experiments unlabeled RNA was transcribed similarly in the presence of 1 mM each of the four nucleotides. The unlabeled RNAs were quantified by visualization on a 2% agarose gel.

A linearized plasmid construct containing the full-length PTH cDNA in Bluescript KS (Invitrogen, CA) was used as previously described (9). For the 3'-UTR of the PTH cDNA, a polymerase chain reaction product (9) was subcloned into pCRII (Invitrogen, CA) (12). The transcripts of 100, 63, 50, and 40 nt (Fig. 1A) were transcribed from polymerase chain reaction products that were subcloned into pGEM-T Easy vector (Promega, WI) (fragment for the 40 and 30 nt) or pCRII (Invitrogen, CA) (fragments for the 100, 63, 50, and 38 nt). For the constructs for transcription of the 100-, 63-, and 50-nt transcripts, polymerase chain reaction was performed with the same 5' oligonucleotide: GTCTCTTCCAATGAT. The 3' oligonucleotide for the 100-nt construct was TTCATGATCATTAAACTTTA, for the 63 nt, AAGTGGAAATGTGTAATACTTTAA, and for the 50 nt, TAATACTTTAAAAAGAAGAATATATTG. For the 40-nt transcript polymerase chain reaction was performed with the 5' oligonucleotide, AATGATTCCATTTCAATAT, and the 3' oligonucleotide, AATACTTTAAAAGAAG. For the transcript of 38 nt the corresponding cDNA was excised from the pCRII 63-nt construct and subcloned into pCRII. The transcript of 30 and 26 nt (Fig. 1A) were prepared from annealed sense and antisense oligonucleotides that were constructed to include the T3 RNA polymerase sequence (underlined). For the 30-nt the sense oligonucleotide was ATTAACCCTCACTAAAGGGACATTTCAATATATTCTTCTTTTTAAAGTATT, and the antisense oligonucleotide was AATACTTTAAAAAGAAGAATATATTGAAATG. For the 26 nt the sense oligonucleotide was ATTAACCCTCACTAAAGGGACAATATATTCTTCTTTTTAAAGTATTA, and the antisense oligonucleotide was TAATACTTTAAAAAGAAGAATATATTG. For the calcium-sensing receptor 3'-UTR, we subcloned the 3'-UTR into Bluescript II KS (Stratagene, La Jolla, CA) using a fragment obtained by restriction of the BoPCaRI cDNA in pSPORT (2) with NotI and SmaI, as previously described (13).

RNA Electrophoretic Mobility Shift Assays (REMSA)-- Labeled RNA transcripts (10,000 cpm) spanning different regions of the PTH 3'-UTR RNA were incubated with S100 thyroparathyroid extracts (10 µg), in a final volume of 20 µl containing 4 µg of tRNA, 10 mM HEPES, 3 mM MgCl2, 40 mM KCl, 5% glycerol, and 1 mM DTT (binding buffer) for 10 min at at 4 °C. In some experiments RNase T1 (Sigma) was added for further 10 min at room temperature to a final concentration of 30 units/µl to digest unprotected RNA. Addition of heparin (5 mg/ml) did not affect binding and the size of the complex. For competition experiments unlabeled RNA was added as indicated. The specificity of binding was further demonstrated by the addition of unlabeled nonrelated transcripts. The samples were run for 3 h on a native 4% polyacrylamide gel (polyacrylamide:bisacrylamide, 70:1) in a cold room. RNA-protein binding was visualized by autoradiography of the dried gels.

UV Cross-linking Assay-- UV cross-linking assays were performed as previously described (9) using 10 µg of S100 thyroparathyroid extracts and 32P-labeled RNA transcripts of the full-length or parts of the 3'-UTR of the PTH cDNA in a buffer containing 10 mM HEPES, 3 mM MgCl2, 40 mM KCl, 5% glycerol, 1 mM DTT, and 5 mg/ml heparin to eliminate nonspecific binding. After UV cross-linking, the samples were digested by RNase A, fractionated by SDS-PAGE, and autoradiographed.

Antisense Oligonucleotides and Binding Interference-- The antisense oligonucleotides used are shown in Fig. 4A. Corresponding sense oligonucleotides were also synthesized. For binding interference experiments antisense oligonucleotides (200 pmol) were mixed with the radiolabeled RNA, heated to 80 °C for 10 min, and cooled slowly to 25 °C, before addition of protein extract and REMSA. In some experiments preincubation of the RNA and oligonucleotides was performed without heating of the RNA. In other experiments annealed double-strand DNAs were added instead of the antisense oligonucleotides.

Construction of the Chimeric GH mRNA containing 63 nt of the PTH mRNA 3'-UTR for in Vitro Degradation Assay-- The 63-base pair DNA corresponding to the PTH mRNA 3'-UTR 63-nt transcript (Fig. 1A) was inserted into the SmaI site of the pS16-GH that contained the S16 ribosomal protein promoter linked to the GH structural gene lacking GH promoter sequences (16). The control was the same plasmid without the PTH mRNA 3'-UTR 63-base pair DNA. The GH DNA with and without the PTH sequence was subcloned into Bluescript KS (Invitrogen, CA) to transcribe RNA.

In Vitro RNA Degradation Assay-- Preparation of S100 PT protein extracts for the RNA degradation assay and the assay itself were performed as before (9). 0.2 × 106 cpm transcripts of PTH, GH, or the chimeric GH/PTH 63-nt RNAs were incubated with 10-20 µg of PT cytoplasmic extracts and 80 units/ml RNasin (Promega, WI) and at timed intervals samples were removed and extracted by Tri-reagent (Molecular Research Center, Cincinnati OH). The labeled RNAs from each sample were run on formaldehyde-agarose gels, transferred to Hybond membranes (Amersham Pharmacia Biotech), and autoradiographed (9). The remaining undegraded transcripts at the different time points were quantified by densitometry.

To measure the effect of PTH sequences in the pCRII polylinker transcript, EcoRV-linearized pCRII plasmids containing the 63 or 38 nt of the PTH 3'-UTR as described above, or the unmodified pCRII polylinker were used to transcribe RNA with the Sp6 RNA polymerase. The resulting transcripts contained ~100 nt corresponding to the polylinker plus the additional PTH sequences (Fig. 6A). They were analyzed by in vitro degradation with PT proteins.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of the Minimal Protein Binding Sequence in the PTH mRNA 3'-UTR-- PT cytosolic proteins specifically bind the full-length PTH mRNA transcript and a transcript for the PTH mRNA 3'-UTR. To identify the protein binding sequence in the PTH mRNA 3'-UTR we analyzed the binding of PT proteins to smaller RNA transcripts of the PTH mRNA 3'-UTR (Fig. 1A). Uniformly labeled transcripts were incubated with PT cytosolic extract and the mixture resolved on native polyacrylamide gels for REMSA. The free probe for all transcripts ran as two major bands. These bands may represent secondary structures of the RNA, because denaturing the RNA at 80 °C followed by slow renaturation at room temperature resulted in a single band on polyacrylamide gel. This renatured probe showed the same binding to PT proteins as the untreated transcript (not shown). The transcripts used for mapping the minimal protein binding element in the PTH 3'-UTR are shown in Fig. 1A. Transcripts of 174 and 38 nt that excluded the 60-terminal nt of the 3'-UTR did not bind proteins. A transcript of 234 nt consisting of the full-length UTR and transcripts of 100 (Fig. 1B), 63, 50, and 40 nt (not shown) of the 3'-UTR showed a large protein-RNA complex on REMSA with PT proteins (Fig. 1B). This complex was reduced to a smaller complex after RNase T1 digestion of the bound protein RNA samples (Fig. 1B). Similar results were obtained when a transcript for the full-length PTH mRNA was analyzed (not shown). Transcripts of 30 (not shown) and 26 nt formed only the smaller protein-RNA complexes with or without treatment with RNase T1 (Fig. 1B) and the larger RNA-protein complex was not formed. These results show that a transcript of 40 nt was necessary for the formation of the larger protein-RNA complex that was obtained when the full-length PTH mRNA 3'-UTR transcript was analyzed. A 26-nt element was sufficient for protein binding and formed a complex that was similar to the complex formed with larger transcripts after treatment with RNase T1. Therefore, additional nucleotides in the 5' of this element were necessary for formation of the larger complex that was formed in the absence of RNase T1. PT protein binding to these smaller transcripts (100, 63, and 40 nt) was increased by hypocalcemia and decreased by hypophosphatemia (Fig. 2), as with the full-length PTH transcript in our previous results (9). These results demonstrate that the regulation of binding is preserved with the smaller transcripts. Further experiments were performed to confirm the minimal binding element.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Different PTH mRNA 3'-UTR transcripts used for binding assays revealed the minimal sequence for protein binding by REMSA. A, the full-length PTH mRNA 3'-UTR (234 nt) and smaller transcripts which were tested for binding by REMSA. The minimal sequence for binding (26 nt) is shown in a lighter shade. The binding of PT proteins by each transcript is indicated on the right. B, REMSA for the binding of parathyroid cytosolic proteins to the 234- (full-length), 100-, and 26-nt transcripts of the 3'-UTR. For each transcript, the free probe is shown (single vertical line) and after digestion with RNase T1 (second lane in each panel). The protein complex formed with each probe in the presence of proteins is shown without RNase T1 (arrow) and after RNase T1 (double vertical lines). All the free probes, except the 26-nt probe, ran as two bands (see "Results").


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Parathyroid protein-binding to the shorter transcripts of the PTH mRNA 3'-UTR is increased in rats fed a low calcium diet and decreased in rats fed a low phosphate diet. UV cross-linking of PT proteins from normal (N), low calcium (-Ca), and low phosphate (-P) rats to transcripts of 100-, 63-, and 40-nt of the PTH 3'-UTR. Molecular mass markers in kDa are indicated on the right. Calcium and phosphate regulated binding to all 3 transcripts.

To demonstrate the specificity of the binding of PT proteins to the protein-binding element we used competitor RNAs from overlapping regions of the 3'-UTR. Fig. 3 shows a representative REMSA that demonstrates the binding of PT cytosolic proteins to the PTH mRNA 3'-UTR. Addition of excess unlabeled RNA transcript for the 3'-UTR that did not include the terminal 60-nucleotide of the 3'-UTR (Fig. 3, transcript A) did not compete for binding of PT proteins to the PTH 3'-UTR. However, excess transcript of the 26-nt element or of 63 nt that included the 26-nt binding element (Fig. 3, transcripts B and C) both competed for protein binding to the 3'-UTR. Excess of an unrelated transcript for the 3'-UTR of the calcium-sensing receptor mRNA (Fig. 3, transcript D), which is also expressed in the PT, did not compete for binding. Addition of heparin had no effect on complex formation (not shown). These results demonstrate the specificity of the protein-RNA interaction and indicate that the 26-nt transcript was sufficient to compete for the binding of PT proteins to the PTH mRNA 3'-UTR.


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 3.   A 26-nt transcript is sufficient to compete for the binding of PT cytosolic proteins with the full-length PTH mRNA 3'-UTR. Competition experiment for the binding of PT proteins to the 3'-UTR by REMSA. PT proteins were incubated with the full-length transcript either without (lane 2) or with ×50 or ×100 of transcript A, the 3'-UTR without the terminal 60 nt; ×25 or ×50 of transcript B, the 26-nt binding element; ×25 or ×50 of transcript C, the 63 nt including the binding element; and ×50 or ×100 of transcript D, the calcium sensing receptor 3'-UTR. After binding the samples were treated with RNase T1 and then separated on native PAGE. Lane 1 shows the labeled transcript after RNase T1 without added protein. There was competition by transcripts B and C, which include the binding element, but not by A and D.

To further characterize the protein binding element in the PTH mRNA 3'-UTR we designed short single stranded antisense DNA oligonucleotides complimentary to portions of the 3'-UTR and analyzed their effect on protein-RNA binding by REMSA and UV cross-linking analysis. Fig. 4A shows the sequence of the 100 terminal nt of the PTH mRNA 3'-UTR including the 26 nt of the proposed protein-binding element and the antisense oligonucleotides used for the binding interference experiments. A representative REMSA for the binding of cytosolic PT proteins to the 3'-UTR transcript that had been preincubated with different antisense oligonucleotides is shown in Fig. 4B. The antisense oligonucleotides were annealed to the labeled 3'-UTR transcript that had been heated to 80 °C to unfold secondary structures in the RNA. PT protein extracts were then added and protein binding analyzed. Corresponding double-stranded DNAs were used as controls. Fig. 4B shows the 3'-UTR transcript after RNase T1 treatment and the protein-RNA complexes formed after addition of PT cytosolic extracts followed by RNase treatment. Preincubation of the PTH mRNA 3'-UTR transcript with antisense oligonucleotides 1, 2, and 6 (Fig. 4A) that did not span the protein binding sequences had no effect on protein binding (Fig. 4B). Preincubation with oligonucleotides spanning the 26-nt element or part of this sequence with or without 3'-flanking sequences (oligonucleotides 3, 4, and 5 in Fig. 4A) abolished the binding of PT proteins to the 3'-UTR (Fig. 4B). Corresponding sense or double-stranded DNAs had no effect on protein-RNA complex formation (not shown). The effect of antisense oligonucleotides on PT protein binding to the PTH RNA 3'-UTR was also analyzed by UV cross-linking experiments. In this assay RNA-binding proteins from cytosolic extracts are cross-linked to labeled transcript in solution and complexes resolved by denaturing SDS-PAGE. Fig. 4C shows that 3 cross-linked protein-RNA complexes of ~110, 60, and 50 kDa were formed when a transcript for the PTH mRNA 3'-UTR was analyzed with PT protein extracts, as in our previous reports (9). When the transcript was denatured at 80 °C and preincubated with the antisense oligonucleotides the same inhibitory effect of the oligonucleotides corresponding to the binding region on protein binding was observed (Fig. 4C), similar to the REMSA (Fig. 4B). When the same UV cross-linking experiment was performed without denaturing the RNA by heating to 80 °C there was no effect of preincubation of the RNA with any of the oligonucleotides (Fig. 4C). In addition, when there was no preheating of the RNA, the relevant oligonucleotides did not interfere with binding also by REMSA (not shown). Together, these results indicate that the protein-binding recognition site of the 3'-UTR includes the element of 26 nt and that this region plays a role in protein-RNA binding. Moreover, the interference of binding only after unfolding the RNA at 80 °C suggests that protein binding to this region is dependent on secondary structures in the RNA.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 4.   Antisense oligonucleotides corresponding to the protein-binding element prevent binding of PT proteins to the PTH mRNA 3'-UTR. A, the nt sequence corresponding to the terminal 100 nt of the 3'-UTR (as shown in Fig. 1A) and the single stranded antisense oligonucleotides used for binding interference are shown. The 26-nt protein-binding element is emphasized in bold. B, REMSA for the binding of PT proteins to the 3'-UTR without and with antisense oligonucleotides. All the samples were treated with RNase T1. Lane 1 shows the digested free probe in the absence of protein. Lane 2, shows the protein-RNA complexes formed in the presence of protein. For lanes 3-8, the RNA transcripts were preincubated at 80 °C with the different antisense oligonucleotides (1-6) depicted in Fig. 3A and then protein binding was analyzed by REMSA. Preincubation with the antisense oligonucleotides 3-5, which correspond to the protein-binding element or parts of it, prevented protein binding to the PTH mRNA 3'-UTR. C, UV cross-linking analysis for the binding of PT proteins to the 3'-UTR without and with antisense oligonucleotides. The assay was performed without (first lane) or after preincubation with antisense oligonucleotides 1-6, as for Fig. 3B either after unfolding at 80 °C (above) or without heating to 80 °C (below). Molecular mass markers (kDa) are shown on the right. Preincubation with the antisense oligonucleotides 3-5, which correspond to the protein-binding element or parts of it, prevented protein binding to the PTH mRNA 3'-UTR only if the RNA was denatured at 80 °C.

Sequence analysis of the 26-nt element in the PTH mRNA revealed high conservation of the rat element in the PTH mRNA 3'-UTR to mouse (23 of 26 nt), human (19 of 26 nt), and canine (19 of 26 nt), with human and canine being identical (Table I). Such conservation of this sequence that lies outside of the coding region, among different species, suggests a functional role for this element.

                              
View this table:
[in this window]
[in a new window]
 
Table I
The 26-nt protein-binding element in the PTH mRNA 3'-UTR is conserved among species

Functionality of the Protein-binding Region of the PTH mRNA 3'-UTR Inserted into Heterologous RNAs-- To demonstrate that the protein-binding region has a role in determining mRNA stability and response to calcium and phosphate, we inserted the fragment for the 63 nt of the PTH mRNA 3'-UTR, which contains the 26-nt element (Fig. 1A), into the structural gene of human growth hormone (GH). This is shown schematically in Fig. 5A. We used these constructs to study whether this inserted 63-nt sequence affected GH mRNA stability in an in vitro degradation assay with PT proteins of rats fed normal, low calcium, or low phosphate diets.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   Insertion of the 63-nt protein-binding region of the PTH mRNA 3'-UTR into GH RNA conferred responsiveness to GH mRNA by PT proteins from rats fed low calcium or low phosphate diets in an in vitro degradation assay. A, schematic representation of the GH mRNA (above) and the chimeric GH mRNA containing the PTH 3'-UTR 63-nt element inserted at the end of the GH coding region (below). B, representative gels of in vitro degradation assays for labeled transcripts for PTH (top), GH (middle), and GH + 63 nt of the PTH 3'-UTR (bottom) with PT proteins from rats fed a normal, low calcium, or low phosphate diet. At timed intervals after protein and RNA incubation samples were removed for RNA analysis. C, time response curves of transcripts for GH + 63 nt of the PTH 3'-UTR after incubation with PT cytosolic proteins as in A (bottom panel). Each point represents the mean ± S.E. of three different experiments. The PTH 63-nt insert into the GH mRNA resulted in stabilization of the transcript with low calcium PT proteins and destabilization with low phosphate PT proteins, similar to the native PTH transcript. The PT proteins from the different diets did not affect the native GH transcript.

The in vitro degradation assay reflects the post-transcriptional regulation of PTH mRNA stability in vivo in response to changes in calcium and phosphate. A low calcium diet increases PTH mRNA levels in vivo and PT proteins from these rats stabilized the full-length PTH transcript using the in vitro degradation assay (Fig. 5B, upper panel, and Ref. 9). A low phosphate diet decreases PTH mRNA levels and led to rapid degradation of the PTH transcript by PT proteins from these rats (Fig. 5B, upper panel, and Ref. 9). We then analyzed the effect of the PTH mRNA 63-nt protein binding sequence on GH mRNA degradation in the presence of these PT proteins. With PT proteins from rats fed a normal diet, the chimeric GH transcript containing 63 nt of the PTH 3'-UTR was degraded more rapidly than the native GH transcript (t1/2 = 130 min: >180 min) (Fig. 5B, middle and bottom panels, normal diet). This suggests that this element is an instability element. We then studied the effect of PT proteins from hypocalcemic or hypophosphatemic rats on degradation of the GH transcripts. When the transcript for the native GH mRNA was analyzed with PT proteins from the different diets, there was no effect on native GH degradation (Fig. 5B, middle panel). In contrast, the chimeric GH transcript was stabilized by PT proteins from low calcium rats and more rapidly degraded with PT proteins of low phosphate rats (t1/2 > 180 min:30 min) (Fig. 5, B, bottom panel, and C), similar to the full-length PTH transcript (Fig. 5B, top panel). Therefore the protein binding sequences in the PTH mRNA 3'-UTR were sufficient to confer responsiveness to changes in PT proteins induced by dietary calcium and phosphate to another mRNA that itself was not regulated by calcium and phosphate.

To determine the specificity of the effect of the protein-binding region, the protein-binding segment of 63 nt was inserted into a random sequence, the pCRII polylinker. In addition a shorter PTH mRNA 3'-UTR RNA of 38 nt, that itself did not bind PT proteins (Fig. 1A) was also inserted at the same site into the pCRII polylinker (Fig. 6A). The stability of the polylinker and chimeric RNAs was determined in the in vitro degradation assay with PT proteins. The PTH mRNA 63 nt was recognized and cleaved more rapidly by the PT extract (t1/2 = 10 ± 2 min, n = 3) than the RNA without the PTH mRNA insert (t1/2 = 35 ± 5 min, n = 3) (Fig. 6). Insertion of the shorter PTH RNA 38 nt did not destabilize the chimeric transcript (t1/2 = 40 ± 5 min, n = 3). These results suggest that the PTH 63-nt RNA destabilized the random RNA sequence of pCRII. This effect was similar to the effect of the 63 nt when it was inserted into a larger transcript, GH RNA, representing a cellular mRNA. The destabilizing effect was dependent on an intact protein-binding transcript, because a shorter transcript that disrupted protein binding did not have the same effect.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Insertion of the 63-nt protein-binding region of the PTH mRNA 3'-UTR into a random pCRII RNA resulted in decreased RNA stability that was dependent upon protein binding. A, cDNA fragments corresponding to 63 or 38 nt of the PTH mRNA 3'-UTR, as in Fig. 1A, were inserted into a polylinker of pCRII. Chimeric transcripts and a transcript of the polylinker were analyzed by in vitro degradation with PT proteins from normal rats. B, the last 3 lanes show the different transcripts at 60 min without added PT protein. The chimeric 63-nt transcript was less stable than the native and the chimeric 38-nt transcript.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have identified by gel shift binding, competition experiments, and the use of single-strand antisense oligonucleotides the minimal sequence of 26 nt for protein binding in the PTH mRNA 3'-UTR. Unlike gel shifts, UV cross-linking identified 40 nt as the smallest binding transcript and not the 26- or 30-nt transcripts. The 26 and 30 nt are part of the 40-nt binding transcript. It is not readily evident why the 26-nt element was not sufficient for protein binding by UV cross-linking. However, protein-RNA binding analysis by REMSA utilizes a native PAGE after incubating protein and RNA and therefore may be more physiological than denaturing gels of UV cross-linked RNA-protein complexes. Single-strand antisense oligonucleotides spanning the 26-nt core binding element, or parts of it, interfered with the binding of PT proteins to the 3'-UTR both by REMSA and UV cross-linking. The antisense data together with the competition experiments with the 26-nt element show that the 26-nt element is important for binding. It is possible that the larger sequence of 40 nt may represent the required sequence for protein-RNA interaction, with the 26 nt representing the core element.

We have previously shown that PT proteins from rats fed a low calcium diet, where there is a marked increase in PTH mRNA levels, have increased binding to the PTH mRNA full-length and 3'-UTR transcripts. In contrast, PT proteins from rats fed a low phosphate diet where there is decrease in PTH mRNA levels, have decreased binding (9). We have now shown that protein binding to shorter transcripts (100, 63, and 40 nt) was also regulated by the different diets by UV cross-linking (Fig. 2). The binding of PT proteins to the 26-nt transcript by REMSA was similarly regulated by calcium and phosphate (not shown). These results demonstrate that the smaller transcripts retain the properties of the previously characterized full-length transcript (9).

The rat PTH mRNA 3'-UTR is 234 nt long. Sequence analysis of the PTH mRNA 3'-UTR of different species revealed a preservation of the 26-nt core protein-binding element in rat, murine, human, and canine 3'-UTRs. In particular, there is a stretch of 14 nt within the element that is present in all four species. In the 26-nt element, the identity among the species varies between 73 and 89%. For instance, the human and rat are 73% identical in the 26-nt element, and only 42% identical in their 3'-UTR (11). The canine and rat are 73% identical in their 26-nt element and 50% identical in their 3'-UTR (17). The human and canine are 100% identical in the 26 nt of the element and only 70% identical in their 3'-UTR. Comparison of the 26-nt sequence in rat and mouse showed 89% identity, however, their 3'-UTRs show a comparable degree of identity. All in all, this analysis suggests that the binding element may represent a functional unit that has been evolutionarily conserved, but sequencing of the 3'-UTR in many other species is needed to establish this conclusion.

One of the PT cytosolic proteins involved in the stabilization of the PTH transcript was identified by affinity chromatography to the PTH mRNA 3'-UTR as AUF1 (12). Gel shift assays showed that recombinant AUF1 bound the full-length, 3'-UTR (12) and shorter transcripts including the 26-nt core element.2 There is no PT cell line and therefore PTH mRNA stability was measured by an in vitro degradation assay with rat PT proteins (9). Recombinant AUF1 stabilized the PTH transcript in the in vitro degradation assay with PT proteins (12).

To study functionality of the protein-binding region, we used the 63-nt sequence to create a chimeric transcript. We inserted a 63-base pair fragment of the PTH 3'-UTR into the structural gene of human GH. The RNA transcribed from this chimeric gene includes the 26-nt core element within the 63 nt of the PTH-binding region. We then studied the effect of the protein-binding region to confer PTH-like responsiveness to calcium and phosphate on a heterologous gene. There is no PT cell line and therefore, to study the effect of the PTH 3'-UTR element on RNA decay, we performed in vitro degradation assays with cytosolic proteins from PT glands. With PT proteins, the chimeric transcript was less stable than the native GH transcript indicating that in this assay, with PT proteins the 63-nt element was an instability element. Furthermore, the chimeric GH mRNA transcript containing the 63 nt of the PTH mRNA responded to PT proteins from low calcium and phosphate similar to the PTH mRNA. Therefore, the 63-nt protein-binding region of the PTH mRNA 3'-UTR is both necessary and sufficient to regulate RNA stability and to confer responsiveness to changes in PT proteins by calcium and phosphate.

To document a correlation between protein-binding and RNA stability, the 63-nt protein-binding region or a shorter sequence of 38 nt that did not bind PT proteins were inserted into a random transcript of pCRII polylinker. The stability of these transcripts and the transcript of the original polylinker were then studied in the in vitro degradation assay with PT proteins from normal rats. The chimeric transcript was destabilized by the 63-nt insert and not by the truncated insert. This indicates that the 63-nt binding element also functions as an instability element in a random sequence. Moreover, the lack of effect of the truncated transcript indicates that a sequence, which binds PT proteins is necessary for the degradatory function in another RNA. A random transcript of a polylinker had been used by others to show that the ribonuclease cleavage site in the alpha -globin 3'-UTR could be conferred to a heterologous RNA (18). Therefore, the effect of the 63 nt on RNA stability was dependent upon an intact protein-binding region both with the native PTH RNA (9) as well as in the heterologous RNAs.

Increasing evidence demonstrates that mRNA decay is an actively regulated process that determines gene expression. This process involves trans-acting protein factors that interact with specific cis-elements in a mRNA and under different physiological conditions leads to rapid decay or stability. Defined elements in mRNAs bind specific RNA-binding proteins and have been shown to mediate in addition to RNA stability, subcellular localization and RNA translation (19, 20). The information encoded by such elements in the RNA can be packaged as primary sequences and secondary or tertiary structures or a combination of both. cis-Elements that determine mRNA stability or instability have been determined in a number of mRNAs. The primary sequence of some of these cis-acting elements is highly conserved among species (21). A well defined example is the adenosine uridine-rich element. Repeats of this AUUUA pentamer in the 3'-UTR of mRNAs of various cytokines targeted them for rapid decay by their interaction with cytoplasmic trans-factors (22, 23). In the brains of Alzheimer's patients there are increased levels of beta -amyloid protein and often the amyloid precursor protein mRNA as well (21). A 29-base element in the 3'-UTR has been defined that is bound by trans-factors and determines the amyloid precursor protein mRNA decay (21). The iron response element is another well defined cis-element. This element in the ferritin 5'-UTR controls translation of this mRNA and in the transferrin receptor mRNA it is present in multiple iterations where it regulates mRNA stability (24, 25). We have now identified a novel cis-element in the PTH mRNA 3'-UTR that determines PTH mRNA stability in response to changes in serum calcium and phosphate.

    ACKNOWLEDGEMENTS

We thank Oded Meuhas for the GH plasmid and Miriam Offner for excellent technical assistance.

    FOOTNOTES

* This work was supported in part by grants from the Israel Science Foundation and the U.S.-Israel Binational Science Foundation (to T.N-M.), Horovitz Foundation, and the Minerva Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Nephrology Services, Hadassah University Hospital, P.O. Box 12000, Jerusalem, Israel 91120. Tel.: 972-2-6436778; Fax: 972-2-6421234; E-mail: tally@cc.huji.ac.il.

Published, JBC Papers in Press, December 5, 2000, DOI 10.1074/jbc.M005471200

2 R. Kilav, J. Silver, and T. Naveh-Many, unpublished data.

    ABBREVIATIONS

The abbreviations used are: PTH, parathyroid hormone; PT, parathyroid; UTR, untranslated region; nt, nucleotide(s); DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis; REMSA, RNA electrophoretic mobility shift assay; GH, growth hormone.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Silver, J., and Kronenberg, H. M. (1996) in Principles of Bone Biology (Bilezikian, J. B. , Raisz, L. G. , and Rodan, G. A., eds) , pp. 325-338, Academic Press, San Diego
2. Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M. A., Lytton, J., and Hebert, J. (1993) Nature 366, 575-580[CrossRef][Medline] [Order article via Infotrieve]
3. Naveh-Many, T., and Silver, J. (1990) J. Clin. Invest. 86, 1313-1319[Medline] [Order article via Infotrieve]
4. Naveh-Many, T., Rahamimov, R., Livni, N., and Silver, J. (1995) J. Clin. Invest. 96, 1786-1793[Medline] [Order article via Infotrieve]
5. Kilav, R., Silver, J., and Naveh-Many, T. (1995) J. Clin. Invest. 96, 327-333[Medline] [Order article via Infotrieve]
6. Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, A., Dusso, A., MacDonald, P., and Brown, A. J. (1996) J. Clin. Invest. 97, 2534-2540[Abstract/Free Full Text]
7. Almaden, Y., Canalejo, A., Hernandez, A., Ballesteros, E., Garcia-Navarro, S., Torres, A., and Rodriguez, M. (1996) J. Bone Miner. Res. 11, 970-976[Medline] [Order article via Infotrieve]
8. Nielsen, P. K., Feldt-Rasmusen, U., and Olgaard, K. (1996) Nephrol. Dial. Transplant. 11, 1762-1768[Abstract]
9. Moallem, E., Silver, J., Kilav, R., and Naveh-Many, T. (1998) J. Biol. Chem. 273, 5253-5259[Abstract/Free Full Text]
10. Hendy, G. N., Kronenberg, H. M., Potts, J. T. J., and Rich, A. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 7365-7369[Abstract]
11. Kemper, B. (1986) CRC Crit. Rev. Biochem. 19, 353-379[Medline] [Order article via Infotrieve]
12. Sela-Brown, A., Silver, J., Brewer, G., and Naveh-Many, T. (2000) J. Biol. Chem. 275, 7424-7429[Abstract/Free Full Text]
13. Epstein, E., Sela-Brown, A., Ringel, I., Kilav, R., King, S. M., Benashski, S. E., Yisraeli, J. K., Silver, J., and Naveh-Many, T. (2000) J. Clin. Invest. 105, 505-512[Abstract/Free Full Text]
14. Buzby, J. S., Brewer, G., and Nugent, D. J. (1999) J. Biol. Chem. 274, 33973-33978[Abstract/Free Full Text]
15. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
16. Levy, S., Avni, D., Hariharan, N., Perry, R. P., and Meyuhas, O. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3319-3323[Abstract]
17. Rosol, T. J., Steinmeyer, C. L., McCauley, L. K., Grone, A., DeWille, J. W., and Capen, C. C. (1995) Gene (Amst.) 160, 241-243[CrossRef][Medline] [Order article via Infotrieve]
18. Wang, Z., and Kiledjian, M. (2000) EMBO J. 19, 295-305[Abstract/Free Full Text]
19. Wilhelm, J. E., and Vale, R. D. (1993) J. Cell Biol. 123, 269-274[Medline] [Order article via Infotrieve]
20. Wilson, G. M., and Brewer, G. (1999) Prog. Nucleic Acids Res. Mol. Biol. 62, 257-291[Medline] [Order article via Infotrieve]
21. Rajagopalan, L. E., and Malter, J. S. (1997) Prog. Nucleic Acids Res. Mol. Biol. 56, 257-286[Medline] [Order article via Infotrieve]
22. Brewer, G. (1991) Mol. Cell. Biol. 11, 2460-2466[Medline] [Order article via Infotrieve]
23. Loflin, P., Chen, C. Y., and Shyu, A. B. (1999) Genes Dev. 13, 1884-1897[Abstract/Free Full Text]
24. Klausner, R. D., Rouault, T. R., and Harford, J. B. (1993) Cell 72, 19-28[Medline] [Order article via Infotrieve]
25. Schlegl, J., Gegout, V., Schlager, B., Hentze, M. W., Westhof, E., Ehresmann, C., Ehresmann, B., and Romby, P. (1997) RNA 3, 1159-1172[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.